Literature DB >> 23851689

Ndfip1 enforces a requirement for CD28 costimulation by limiting IL-2 production.

Natalia Ramos-Hernández1, Hilda E Ramon, Allison M Beal, Ami Laroche, Erin A Dekleva, Paula M Oliver.   

Abstract

Although the pathways that permit IL-2 production and the full activation of T cells upon Ag encounter are fairly well defined, the negative regulatory circuits that limit these pathways are poorly understood. In this study, we show that the E3 ubiquitin ligase adaptor Ndfip1 directs one such negative regulatory circuit. T cells lacking Ndfip1 produce IL-2, upregulate IL-2Rα, and proliferate, in the absence of CD28 costimulation. Furthermore, T cells in mice lacking both Ndfip1 and CD28 become activated, produce IL-4, and drive inflammation at barrier surfaces. Ndfip1 constrains T cell activation by limiting the duration of IL-2 mRNA expression after TCR stimulation. Ndfip1 and IL-2 have a similar expression pattern, and, following TCR stimulation, expression of both Ndfip1 and IL-2 requires the activity of NFAT and Erk. Taken together, these data support a negative regulatory circuit in which factors that induce IL-2 expression downstream of TCR engagement also induce the expression of Ndfip1 to limit the extent of IL-2 production and, thus, dampen T cell activation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23851689      PMCID: PMC3853121          DOI: 10.4049/jimmunol.1203571

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  The E3 ubiquitin ligase adaptor Ndfip1 regulates Th17 differentiation by limiting the production of proinflammatory cytokines.

Authors:  Hilda E Ramon; Allison M Beal; Yuhong Liu; George Scott Worthen; Paula M Oliver
Journal:  J Immunol       Date:  2012-03-07       Impact factor: 5.422

2.  Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation.

Authors:  Maximilian Diehn; Ash A Alizadeh; Oliver J Rando; Chih Long Liu; Kryn Stankunas; David Botstein; Gerald R Crabtree; Patrick O Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

3.  Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction.

Authors:  Myung-Shin Jeon; Alex Atfield; K Venuprasad; Connie Krawczyk; Renu Sarao; Chris Elly; Chun Yang; Sudha Arya; Kurt Bachmaier; Leon Su; Dennis Bouchard; Russel Jones; Mathew Gronski; Pamela Ohashi; Teiji Wada; Debra Bloom; C Garrison Fathman; Yun-Cai Liu; Josef M Penninger
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

Review 4.  T-cell anergy.

Authors:  Fernando Macián; Sin-Hyeog Im; Francisco J García-Cózar; Anjana Rao
Journal:  Curr Opin Immunol       Date:  2004-04       Impact factor: 7.486

5.  Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody.

Authors:  M K Jenkins; C A Chen; G Jung; D L Mueller; R H Schwartz
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

6.  CD28 costimulation prevents cell death during primary T cell activation.

Authors:  P J Noel; L H Boise; J M Green; C B Thompson
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

7.  Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness.

Authors:  H Quill; R H Schwartz
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

8.  CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.

Authors:  C B Thompson; T Lindsten; J A Ledbetter; S L Kunkel; H A Young; S G Emerson; J M Leiden; C H June
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

9.  Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b.

Authors:  Connie M Krawczyk; Russell G Jones; Alexandre Atfield; Kurt Bachmaier; Sudha Arya; Bernhard Odermatt; Pamela S Ohashi; Josef M Penninger
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

10.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.

Authors:  P S Linsley; W Brady; L Grosmaire; A Aruffo; N K Damle; J A Ledbetter
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more
  10 in total

1.  The Ubiquitin Ligase Adaptor NDFIP1 Selectively Enforces a CD8+ T Cell Tolerance Checkpoint to High-Dose Antigen.

Authors:  Mayura V Wagle; Julia M Marchingo; Jason Howitt; Seong-Seng Tan; Christopher C Goodnow; Ian A Parish
Journal:  Cell Rep       Date:  2018-07-17       Impact factor: 9.423

2.  Increased peripheral IL-4 leads to an expanded virtual memory CD8+ population.

Authors:  Vanessa Kurzweil; Ami LaRoche; Paula M Oliver
Journal:  J Immunol       Date:  2014-05-02       Impact factor: 5.422

3.  Ndfip1 mediates peripheral tolerance to self and exogenous antigen by inducing cell cycle exit in responding CD4+ T cells.

Authors:  John A Altin; Stephen R Daley; Jason Howitt; Helen J Rickards; Alison K Batkin; Keisuke Horikawa; Simon J Prasad; Keats A Nelms; Sharad Kumar; Lawren C Wu; Seong-Seng Tan; Matthew C Cook; Christopher C Goodnow
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

4.  Higher percentage of CD3⁺CD154⁺ T lymphocytes predicts efficacy of TNF-α inhibitors in active axial SpA patients.

Authors:  Zhiming Lin; Qu Lin; Zetao Liao; Qiuxia Li; Fucheng Zhang; Qiujing Wei; Shuangyan Cao; Jieruo Gu
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

5.  Ndfip-mediated degradation of Jak1 tunes cytokine signalling to limit expansion of CD4+ effector T cells.

Authors:  Claire E O'Leary; Christopher R Riling; Lynn A Spruce; Hua Ding; Suresh Kumar; Guoping Deng; Yuhong Liu; Steven H Seeholzer; Paula M Oliver
Journal:  Nat Commun       Date:  2016-04-18       Impact factor: 14.919

6.  The Nedd4-2/Ndfip1 axis is a negative regulator of IgE-mediated mast cell activation.

Authors:  Kwok Ho Yip; Natasha Kolesnikoff; Nicholas Hauschild; Lisa Biggs; Angel F Lopez; Stephen J Galli; Sharad Kumar; Michele A Grimbaldeston
Journal:  Nat Commun       Date:  2016-10-27       Impact factor: 14.919

7.  Ndfip1 restricts Th17 cell potency by limiting lineage stability and proinflammatory cytokine production.

Authors:  Awo Akosua Layman; Stephanie Sprout; Dylan Phillips; Paula M Oliver
Journal:  Sci Rep       Date:  2017-01-04       Impact factor: 4.379

8.  Ndfip1 restricts mTORC1 signalling and glycolysis in regulatory T cells to prevent autoinflammatory disease.

Authors:  Awo Akosua Kesewa Layman; Guoping Deng; Claire E O'Leary; Samuel Tadros; Rajan M Thomas; Joseph M Dybas; Emily K Moser; Andrew D Wells; Nicolai M Doliba; Paula M Oliver
Journal:  Nat Commun       Date:  2017-06-05       Impact factor: 14.919

Review 9.  Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer.

Authors:  Ewelina Grywalska; Marcin Pasiarski; Stanisław Góźdź; Jacek Roliński
Journal:  Onco Targets Ther       Date:  2018-10-04       Impact factor: 4.147

10.  The E3 ubiquitin ligase Itch restricts antigen-driven B cell responses.

Authors:  Emily K Moser; Jennifer Roof; Joseph M Dybas; Lynn A Spruce; Steven H Seeholzer; Michael P Cancro; Paula M Oliver
Journal:  J Exp Med       Date:  2019-07-16       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.